Nexgel, Inc · NASDAQ:NXGL
Nexgel — Investor Presentation (June 2026)
16 slides from Nexgel's investor presentation, June 2026
Slide 1: BioNx Surgical Introduction
BioNx Surgical Introduction INVESTOR PRESENTATION JUNE 2026 (NASDAQ: NXGL)
Slide 2: Forward Looking Statements
Portfolio FORWARDAccomplishments LOOKING STATEMENTS This presentation contains certain forward-looking statements, including those relating to the Company’s product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential
Slide 3: Key Investor Highlights
KEY INVESTOR HIGHLIGHTS ✓ Completed recent asset purchase transaction with Celularity. ✓ Reset NexGel around highest-convection capabilities. ✓ Increase focus in Medtech/Life Science mission. ✓ Acquired a blue-chip roster of talent across multiple functional areas and led by a renowned foot & ankle
Slide 4: Refocused, Rebuilt, Re-Energized
REFOCUSED, REBUILT, RE-ENERGIZED BEFORE TRANSFORMATION TODAY ▪ Founded as high-quality hydrogel ▪ NexGel Inc. acquired diversified portfolio of ▪ Market-facing gateway for surgeon manufacturer with medical device established regenerative biomaterial engagement that translates clinical pipeline. prod
Slide 5: Our Strategic Partner: Fountainhead LifeSciences
OUR STRATEGIC PARTNER: FOUNTAINHEAD LIFESCIENCES Fountainhead is built for the surgeon and procedural specialists experience, we are aligning innovation, technology, training and education to advance procedural excellence. Fountainhead is the platform that powers the full ecosystem, bringing togethe
Slide 6: Fountainhead Group of Companies
FOUNTAINHEAD GROUP OF COMPANIES • Engineering Design • 10 - Polymer & Resin Printers • Prototyping • Post Processing Milling & Machining • Intellectual Property • FDA Regulatory Assistance • FDA Regulatory • Contract Manufacturing • Quality Management System • Product Commercialization • 13 ISO Clas
Slide 7: Fountainhead: A Quiet Giant in the Private Sector with BioNx Surgical
FOUNTAINHEAD: A QUIET GIANT IN THE PRIVATE SECTOR WITH BIONX SURGICAL ▪ 35 Cleared 510k’s ▪ BioNx steady flow of products + o Average time for concept to clearance is Fountainhead becomes BioNx R&D 15 months. Partner ▪ 21 Issued patents ▪ Products include: oSpine ▪ 12 Pending Applications oTrauma ▪
Slide 8: A Vertically Integrated Life Sciences Platform
A VERTICALLY INTEGRATED LIFE SCIENCES PLATFORM FOUNTAINHEAD “The LifeSciences Platform” Lockhill Sequence MANUFACTURING TRAINING BIONX CADAVER BIONX SURGICAL LAB SURGICAL “The “The Ecosystem” “The Gateway” Integrator” INNOVATION EDUCATION Nvision Aequitas (NASDAQ: NXGL) Copyright © 2026. NexGel, INC
Slide 9: BioNx Surgical: Commercialization & Engagement Gateway
BIONX SURGICAL: COMMERCIALIZATION & ENGAGEMENT GATEWAY Unified Market-Facing Engagement Gateway ▪ BioNx is NOT just another portfolio company, it is the commercial interface of the entire platform (first interaction for surgeons and other procedural specialist to everything on the platform). ▪ We f
Slide 10: End State Vision and Value Creation
END STATE VISION AND VALUE CREATION Scaled Life Sciences Platform ▪ Aiming to build a large, integrated platform generating over $250M revenue with a surgeon-centered approach. Value Creation Drivers ▪ Growth fueled by revenue increase and multiple expansion through defensibility, integration, and
Slide 11: Growing the Product Portfolio
GROWING THE PRODUCT PORTFOLIO Currently Available Upcoming Target Date Reimbursement Type BioVance Private Pay Sentry Silverseal July 2026 Wound Care Activate First Quarter 2027 Medicare Shelter TBD Interfyl BioVance 3L Forma Surgical BioVance SL Sentinel Lucent - SL August 2026 Radiant - DL August
Slide 12: Consumer Products Division
CONSUMER PRODUCTS DIVISION (NASDAQ: NXGL) Copyright © 2026. NexGel, INC. All Rights Reserved. 12
Slide 13: Experienced Leadership Team
EXPERIENCED LEADERSHIP TEAM NEXGEL FOUNTAINHEAD Adam Levy Dr. Steve Brigido, DPM Brian Kieser, CPA Kevin Harris, CFA CEO, NexGel President & Clinical Architect, CEO, Fountainhead Chief Operating Officer BioNx Surgical Ian Blackman, CPA Desiree Long Pete Martinez Denise Alva Chief Financial Officer,
Slide 14: 4-Stages of Growth Strategy and Milestones
4-STAGES OF GROWTH STRATEGY AND MILESTONES Stage 1 — Foundation: Prove the closed-loop model by building one high-quality CadaverLab, seeding a core surgeon network, and establishing early evidence that surgeon insight meaningfully connects to product outcomes. Stage 2 — Integration: Formalize the e
Slide 15: Investment Summary
INVESTMENT SUMMARY • Acquired a diversified portfolio of regenerative biomaterial products from Celularity, establishing a foundation in tendon repair, skin grafts, and bone growth. • Built BioNx Surgical as NexGel's commercial gateway — a surgeon-centric platform connecting innovation, training, an
Slide 16: Contact Us
Contact Us Investor Relations KCSA Strategic Communications Valter Pinto, Managing Director PH: (212) 896-1254 NEXGEL@KCSA.com